Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy

Retrospective Study of Metastatic Left Colon and Rectal Cancer as Regard Treatment With Anti_EGFR Targeted Therapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06083974

Acronym

EGFR

Enrollment

100

Registered

2023-10-16

Start date

2015-01-01

Completion date

2022-12-30

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Colorectal Adenocarcinoma

Keywords

EGFR, Targeted therapy ,metastatic colorectal cancer

Brief summary

Colorectal cancer ranks the second lethal cancer and third prevalent malignant tumour worldwide, Despite of different odern modalities for diagnosis,large number of cases diagnosed at metastatic advanced stage . New treatment approach has been discovered habe been discovered making a huge revolution in metastatic colorectal cancer represented by targeted therapy including anti\_EGFR ,anti\_angiogenic and kinase inhibitors .

Detailed description

Retrospective study aims to evaluate the effect of EGFR expression in metastatic colorectal cancer and the outcome of treatment with anti\_EGFR targeted therapy between left colon and rectal cancer

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. age above 18 2. Both sex 3. Performance status zero to one according to ECOG scale system 4. Histo-pathologial diagnosis adenocarcinoma of left colon or rectum. 5. Patients diagnosed with left colon and rectal cancer. 6. Patients eligible to receive chemotherapy (with renal and liver chemistry, and normal CBC. 7. Patients diagnosed with metastatic stage. 8. K-RAS wild type.

Exclusion criteria

1. Second malignancy 2. Histo-pathological types other than adenocarcinoma. 3. Right colon cancer patients. 4. Patients refused receiving anti\_EGFR targeted therapy. 5. Patients with any abnormalities preventing to receive chemotherapy. 6. Early stages of colorectal cancer. 7. K-RAS mutant type.

Design outcomes

Primary

Measure	Time frame	Description
OS and DFS of patients with metastatic colorectal cancer patients received anti_EGFR targeted therapy	Anti_EGFR targeted therapy in assuit university hospitals from 2015 to 2022	Evaluation of anti-EGFR targeted therapy on metastatic cancer rectum and left colon and factors affecting response to treatment

Secondary

Measure	Time frame	Description
Response rate (RR) in patients received chemotherapy only or with combination with targeted therapy.	The response of patients to EGFR targeted therapy in AUH at period from 2015 to 2022	Factors affecting response to targeted therapy

Outcome results